MHRA approves Bimervax as a booster for COVID 19 patients
The Medicines and Healthcare products Regulatory Agency (MRHA) has authorised HIPRA Human Health’s COVID-19 vaccine, Bimervax, after it met the regulator’s required safety, quality and effectiveness standards
HIPRA, a biotech company that provides vaccines and diagnostic services, developed Bimervax, which combines part of the SARS-CoV-2 virus spike protein with an additional ingredient designed to trigger a stronger immune response, known as an adjuvant.
The new COVID-19 vaccine will be given as a booster injection to eligible individuals aged 16 years and over. The regulator’s decision was based on data from a study of 765 adults who received primary vaccination with two doses of the Comirnaty COVID-19 vaccine and then a booster dose of either Bimervax or Comirnaty.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.